The second-generation ALK-TKIs alectinib (brain response rate, 52.4%) and ceritinib (brain response rate, 42.1%) were used to treat NSCLC-BM patients with ALK active mutation and crizotinib resistance. Here, ALK is linked to non-small cell lung carcinoma.